Similar articles

• Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.

  Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A. Rody A, et al. Zentralbl Gynakol. 2006 Apr;128(2):76-81. doi: 10.1055/s-2006-921508. Zentralbl Gynakol. 2006. PMID: 16673249 Clinical Trial.
• Concordance among gene-expression-based predictors for breast cancer.

  Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. Fan C, et al. N Engl J Med. 2006 Aug 10;355(6):560-9. doi: 10.1056/NEJMoa052933. N Engl J Med. 2006. PMID: 16899776
• Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.

  Huber KE, Carey LA, Wazer DE. Huber KE, et al. Semin Radiat Oncol. 2009 Oct;19(4):204-10. doi: 10.1016/j.semradonc.2009.05.004. Semin Radiat Oncol. 2009. PMID: 19732684 Review.
• The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response.

  Loi S, Piccart M, Sotiriou C. Loi S, et al. Crit Rev Oncol Hematol. 2007 Mar;61(3):187-94. doi: 10.1016/j.critrevonc.2006.09.005. Epub 2006 Nov 7. Crit Rev Oncol Hematol. 2007. PMID: 17088071 Review.
• Gene-expression-based predictors for breast cancer.

  Goetz MP, Ingle JN, Couch FJ. Goetz MP, et al. N Engl J Med. 2007 Feb 15;356(7):752; author reply 752-3. doi: 10.1056/NEJMc062416. N Engl J Med. 2007. PMID: 17301312 No abstract available.